Source: International Congress 2016 – Molecular footprints in lung cancer diagnosis and management



Rating:

Share or cite this content

Citations should be made in the following way:
Torsten Gerriet Blum (Berlin, Germany). Molecular predictors of disease progression: have we made any progress?. International Congress 2016 – Molecular footprints in lung cancer diagnosis and management

Member's Comments

No comment yet.

Related content which might interest you: Monitoring disease progression in COPD patients: one step beyond! Source: Eur Respir J 2014; 43: 665-667 Year: 2014 Complexity in chronic asthma and COPD: implications for risk assessment, disease progression and control Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium Year: 2008 What is the best biomarker of COVID-19 pneumonia progression? Source: Virtual Congress 2021 – COVID - 19 biomarkers Year: 2021 Molecular imaging of the progression of pulmonary fibrosis using animal models of disease Source: Eur Respir J 2006; 28: Suppl. 50, 605s Year: 2006 Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations Source: Eur Respir J, 55 (3) 1901957; 10.1183/13993003.01957-2019 Year: 2020 Late Breaking Abstract - Molecular mechanisms involved in early stage of pulmonary hypertension: experimental study Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension Year: 2018 Late Breaking Abstract - Prognostic value of serum biomarkers in patients with idiopathic pulmonary fibrosis and correlation with disease progression. Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases Year: 2021 Molecular biology of advanced NSCLC and survival: seeking the best therapy Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression? Source: Eur Respir J , 49 (2) 1602345; DOI: 10.1183/13993003.02345-2016 Year: 2017 Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression? Source: Eur Respir J , 49 (2) 1602524; DOI: 10.1183/13993003.02524-2016 Year: 2017 Projections of the future burden of COPD in the Netherlands by disease severity using a dynamic population model of disease progression Source: Eur Respir J 2004; 24: Suppl. 48, 700s Year: 2004 Cytomegalovirus: an unrecognised potential contributor to cystic fibrosis disease progression? Source: Eur Respir J, 53 (4) 1801727; 10.1183/13993003.01727-2018 Year: 2019 Initial clinical phenotype of COPD: Correlation with the natuaral history of the disease Source: Annual Congress 2011 - COPD management Year: 2011 Advances in knowledge of global epidemiology, pathogenesis and risk factors Source: Annual Congress 2008 - PG12 - Challenges in pulmonary embolism: hot issues and interactive cases (jointly organised with ACCP) Year: 2008 Imaging and molecular biomarkers: a novel approach to screen populations at risk of pulmonary fibrosis? Source: Eur Respir J 2016; 48: 1271-1273 Year: 2016